MXPA05002444A - Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. - Google Patents

Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.

Info

Publication number
MXPA05002444A
MXPA05002444A MXPA05002444A MXPA05002444A MXPA05002444A MX PA05002444 A MXPA05002444 A MX PA05002444A MX PA05002444 A MXPA05002444 A MX PA05002444A MX PA05002444 A MXPA05002444 A MX PA05002444A MX PA05002444 A MXPA05002444 A MX PA05002444A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
therapeutic
methods
therapeutic agents
relates
Prior art date
Application number
MXPA05002444A
Other languages
English (en)
Spanish (es)
Inventor
Mark E Davis
Original Assignee
Insert Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31982363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05002444(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insert Therapeutics Inc filed Critical Insert Therapeutics Inc
Publication of MXPA05002444A publication Critical patent/MXPA05002444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/282—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing two or more oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Primary Health Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Business, Economics & Management (AREA)
MXPA05002444A 2002-09-06 2003-09-04 Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. MXPA05002444A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40885502P 2002-09-06 2002-09-06
US42283002P 2002-10-31 2002-10-31
US45199803P 2003-03-04 2003-03-04
PCT/US2003/027588 WO2004022099A2 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto

Publications (1)

Publication Number Publication Date
MXPA05002444A true MXPA05002444A (es) 2005-09-30

Family

ID=31982363

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA05002444A MXPA05002444A (es) 2002-09-06 2003-09-04 Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
MX2013004590A MX367615B (es) 2002-09-06 2003-09-04 Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013004590A MX367615B (es) 2002-09-06 2003-09-04 Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.

Country Status (17)

Country Link
US (20) US7270808B2 (enExample)
EP (4) EP3332811A1 (enExample)
JP (4) JP2006502301A (enExample)
KR (6) KR101476067B1 (enExample)
CN (2) CN104383554B (enExample)
AT (1) ATE533513T1 (enExample)
AU (2) AU2003278764C1 (enExample)
BR (2) BRPI0314042B8 (enExample)
CA (1) CA2497792C (enExample)
CY (2) CY1112362T1 (enExample)
ES (3) ES2377318T3 (enExample)
HK (1) HK1254600A1 (enExample)
IL (2) IL234716A0 (enExample)
MX (2) MXPA05002444A (enExample)
PT (2) PT2277551E (enExample)
TW (2) TWI366464B (enExample)
WO (1) WO2004022099A2 (enExample)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
AU2003209227A1 (en) 2002-01-14 2003-07-30 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
EP1534269B1 (en) 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
AU2003278764C1 (en) 2002-09-06 2010-09-16 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2004032862A2 (en) * 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
JP4009721B2 (ja) * 2003-05-23 2007-11-21 独立行政法人産業技術総合研究所 イオン結合性ポリマー含有基板、該基板を含有する検出用センサー及び病原菌又は病原菌が生産する毒素の検出方法
US7790150B2 (en) * 2003-09-05 2010-09-07 The General Hospital Corporation Dual phase drug release system
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
KR20120073370A (ko) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
JP2008501314A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド 線状又は分枝状糖ポリマーの存在下でタンパク質を折り畳むための方法及びキット
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5107716B2 (ja) * 2004-11-05 2012-12-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 分子治療用生分解性リンカー
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
JP2008545652A (ja) * 2005-05-17 2008-12-18 プレキシコン，インコーポレーテッド ｃ−ｋｉｔおよびｃ−ｆｍｓ活性を調節する化合物およびその用途
WO2007002325A1 (en) * 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
WO2007009265A1 (en) * 2005-07-22 2007-01-25 The Governors Of The University Of Alberta Tec Edmonton NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20070072904A1 (en) * 2005-09-07 2007-03-29 Jack Lin PPAR active compounds
CA2621275A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
US20080249137A1 (en) * 2005-09-07 2008-10-09 Jack Lin PPAR active compounds
WO2007072481A2 (en) * 2005-12-19 2007-06-28 Capsutech Ltd. Cyclodextrin-containing polymers and uses thereof
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
CN103420877B (zh) 2006-03-29 2015-08-12 诺瓦提斯公司 基于异羟肟酸酯的选择性mmp抑制剂
US20080027212A1 (en) * 2006-06-28 2008-01-31 Skinner Keith K Methods and compositions for improved uptake of biological molecules
MX2009000646A (es) 2006-07-20 2009-01-29 Novartis Ag Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp).
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2009005780A (es) 2006-11-30 2009-06-10 Nektar Therapeutics Al Corp Metodo para preparar un conjugado de polimeros.
TWI528976B (zh) * 2006-12-13 2016-04-11 斯茹林製藥公司 用於醫物傳遞之以環糊精為基之聚合物
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
JP2010516625A (ja) * 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
JP2010518120A (ja) * 2007-02-09 2010-05-27 エンゾン ファーマスーティカルズ インコーポレイテッド ７−エチル−１０−ヒドロキシカンプトテシンのマルチアームポリマー複合体を用いた抵抗性または難治性の癌の治療方法
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0814423B1 (pt) * 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
KR20100065190A (ko) * 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
JP5597396B2 (ja) * 2007-09-28 2014-10-01 ナノデックス株式会社 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR IMPROVING INFLAMMATION OF SN, PSYCHOSIS, DELI, PTSD OR PTSD
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
PL2229356T3 (pl) 2007-12-03 2012-03-30 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
EP2268612B1 (en) 2008-03-24 2014-08-20 Novartis AG Arylsulfonamide-based matrix metalloprotease inhibitors
EP2269072B1 (en) * 2008-03-31 2017-08-23 Boston Medical Center Corporation Predictive marker for topoisomerase i inhibitors
EP2283133A2 (en) 2008-04-04 2011-02-16 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009152087A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
EP2313411A1 (en) * 2008-06-10 2011-04-27 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor
EP2331140B1 (en) * 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010019718A2 (en) 2008-08-13 2010-02-18 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068283A1 (en) 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex VIVO modifiable particle or polymeric material medicament carrier
HRP20192120T1 (hr) 2008-09-23 2020-02-21 Nektar Therapeutics Postupak metronomskog doziranja kamptotecinskih prolijekova (e.g.peg-irinotekan)
US20100098654A1 (en) * 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
EP2359852A4 (en) * 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
CN102307473A (zh) * 2008-12-10 2012-01-04 摩萨纳医疗有限公司 可生物降解的生物相容性喜树碱-聚合物共轭物的药物制剂
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
WO2010099466A2 (en) 2009-02-26 2010-09-02 The Regents Of The University Of California A supramolecular approach for preparation of size controllable nanoparticles
AU2010224184A1 (en) * 2009-03-11 2011-09-29 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of Raf kinases
SG174257A1 (en) * 2009-03-11 2011-10-28 Plexxikon Inc Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
JP5511942B2 (ja) 2009-04-03 2014-06-04 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト 組成物及びその使用
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20120077774A1 (en) * 2009-05-28 2012-03-29 Cornell University Compositions and their use for removing cholesterol
JP5747432B2 (ja) * 2009-05-28 2015-07-15 国立大学法人秋田大学 ２置換修飾シクロデキストリンおよびこれを用いた核酸検出方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20110152512A1 (en) * 2009-09-09 2011-06-23 John Ryan Cyclodextrin-based polymers for therapeutics delivery
AU2010295646B2 (en) * 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
US8460745B2 (en) * 2009-09-20 2013-06-11 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
CA2780190C (en) 2009-11-06 2020-05-05 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
MX2012005827A (es) * 2009-11-18 2012-06-19 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
US20110237540A1 (en) * 2009-11-23 2011-09-29 Crawford Thomas C Cyclodextrin-based polymers for therapeutic delivery
JP5815558B2 (ja) * 2009-12-23 2015-11-17 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物及び方法ならびにそれらの適応症
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20120004195A1 (en) * 2010-01-19 2012-01-05 Alexandra Glucksmann Cyclodextrin-based polymers for therapeutic delivery
JP2011190341A (ja) * 2010-03-15 2011-09-29 Nano Dex Kk シクロデキストリン化合物
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
CA2799202C (en) * 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012044832A1 (en) * 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012092339A2 (en) * 2010-12-28 2012-07-05 The Children's Hospital Of Philadelphia The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
SI2672967T1 (sl) 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
WO2013170655A1 (en) 2012-01-18 2013-11-21 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
CN104203985A (zh) * 2012-01-31 2014-12-10 天蓝制药公司 用于治疗性递送的环糊精类聚合物
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
JP5909593B2 (ja) * 2012-03-13 2016-04-26 ポハン工科大学校 産学協力団Ｐｏｓｔｅｃｈ Ａｃａｄｅｍｙ−Ｉｎｄｕｓｔｒｙ Ｆｏｕｎｄａｔｉｏｎ 放出制御が可能な薬物伝達複合体、及びその利用
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9598503B2 (en) * 2012-04-18 2017-03-21 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014028209A1 (en) 2012-08-14 2014-02-20 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
HK1212618A1 (zh) 2012-10-16 2016-06-17 恩多塞特公司 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
WO2014070233A1 (en) 2012-10-29 2014-05-08 Boston Medical Center Corporation Brca1 mutations as predictive markers for topoisomerase i inhibitors
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US9919059B2 (en) 2012-12-10 2018-03-20 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
CN103044349B (zh) * 2012-12-13 2014-05-21 浙江大学 一种微波辅助纳米铁酸盐制备乙二胺四乙酸酐的方法
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
US9566247B2 (en) 2013-02-25 2017-02-14 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP2972349B1 (en) 2013-03-14 2019-10-23 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
CA2903293C (en) 2013-03-15 2020-10-13 Plexxikon Inc. Heterocyclic compounds and uses thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014194127A1 (en) 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN106413634B (zh) 2013-11-01 2019-03-05 雷恩斯根公司 双部件调节性人工晶状体设备
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015179402A1 (en) * 2014-05-19 2015-11-26 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
CN110478495A (zh) 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
CN104274837B (zh) * 2014-09-18 2017-01-11 福格森（武汉）生物科技股份有限公司 一种尼洛替尼口服制剂
CN104311820B (zh) * 2014-09-24 2017-06-20 北京化工大学 一种基于多糖接枝聚天冬氨酸苄酯构建可降解药物载体的方法
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI547308B (zh) * 2015-06-10 2016-09-01 聚和國際股份有限公司 聚電解質膠囊的製備方法及所製得的聚電解質膠囊
ES2980216T3 (es) 2015-07-01 2024-09-30 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
WO2017006279A1 (en) * 2015-07-08 2017-01-12 Aten Porus Lifesciences Cyclodextrin-polymer complexes and compostions and methods of making and using the same
KR102716928B1 (ko) * 2015-07-22 2024-10-11 닛토덴코 가부시키가이샤 나노 입자 동결건조물 형태를 위한 조성물 및 방법
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN108463244B (zh) 2015-08-04 2022-05-27 杜克大学 用于递送的基因编码的固有无序隐形聚合物及其使用方法
AU2016328619B2 (en) 2015-09-21 2020-07-16 Opna Bio SA Heterocyclic compounds and uses thereof
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
JP6900376B2 (ja) 2015-12-01 2021-07-07 レンスゲン、インコーポレイテッド 調節式眼内レンズデバイス
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
KR20180104308A (ko) * 2016-01-21 2018-09-20 아텐 포러스 라이프사이언시즈 시클로덱스트린계 폴리머, 이의 제조방법, 조성물 및 용도
WO2017176796A1 (en) 2016-04-04 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for preventing and treating disease
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
CN110023326A (zh) 2016-09-23 2019-07-16 杜克大学 具有lcst行为的非结构化无重复多肽
JP7330101B2 (ja) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
WO2018119422A1 (en) 2016-12-22 2018-06-28 Duke University Polycationic microfibers and methods of using the same
WO2018136202A2 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
CA3048785A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
EP3600338A4 (en) 2017-03-28 2020-10-28 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
CN111263758A (zh) 2017-06-30 2020-06-09 麻省理工学院 支链的多官能大分子单体和相关聚合物及其用途
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
US11319320B2 (en) 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
IL313068A (en) 2017-11-07 2024-07-01 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
US12460050B2 (en) 2017-11-15 2025-11-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
JP7366028B2 (ja) 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びその抗体コンジュゲート
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
AU2019239952A1 (en) 2018-03-20 2020-10-08 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
WO2019213150A1 (en) * 2018-04-30 2019-11-07 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
JP7590871B2 (ja) 2018-05-09 2024-11-27 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗ｍｓｒ１抗体及びその使用方法
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
US10988491B2 (en) 2018-08-17 2021-04-27 Massachusetts Institute Of Technology Degradable polymers of a cyclic silyl ether and uses thereof
EP3902841B1 (en) 2018-12-28 2025-01-29 The University of North Carolina at Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
EP3806818B1 (en) * 2018-12-29 2021-11-24 Wacker Chemie AG Hydrophilic cyclodextrin-containing silicone gels
US12433870B2 (en) 2019-01-31 2025-10-07 Northwestern University Supramolecular photoprotection of a photosensitizer
EP3953351A1 (en) 2019-04-09 2022-02-16 Plexxikon Inc. Condensed azines for ep300 or cbp modulation and indications therefor
US20210317143A9 (en) 2019-05-20 2021-10-14 Massachusetts Institute Of Technology Boronic ester prodrugs and uses thereof
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
KR20210071296A (ko) * 2019-12-06 2021-06-16 (주) 에이치엔에이파마켐 공유결합성 유기 골격체 및 폴리머를 이용한 경피전달용 복합체
WO2021113625A1 (en) 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
WO2021141662A1 (en) 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
CN111443068B (zh) * 2020-03-06 2023-06-27 天津大学 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用
TW202204354A (zh) 2020-04-02 2022-02-01 美商普雷辛肯公司 用於ｃｓｋ調節之化合物及方法以及其說明
WO2021216898A1 (en) 2020-04-23 2021-10-28 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
KR20230028254A (ko) 2020-04-29 2023-02-28 플렉시콘 인코퍼레이티드 헤테로사이클릭 화합물의 합성
NL2025818B1 (en) * 2020-06-11 2022-02-16 Umc Utrecht Holding Bv Improved adhesive drug carrier
EP4164658A4 (en) * 2020-06-15 2024-06-12 Nanosynthons LLC EXCIPIENTS FOR IMPROVED WATER STABILIZATION AND SOLUBILIZATION AND THEIR USES
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022061251A1 (en) 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN112755197B (zh) * 2020-10-09 2023-01-13 黑龙江大学 一种环糊精药物包合物及其制备方法和应用
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure
EP4284919A1 (en) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CN115160454A (zh) * 2021-04-01 2022-10-11 四川大学 一种基于聚-β-环糊精与金刚烷主客体作用的超分子多醛化合物及其制备方法
CN113274541A (zh) * 2021-05-10 2021-08-20 四川大学 一种抗菌型胶原基医用材料及其制备方法
WO2022240966A1 (en) 2021-05-11 2022-11-17 Opna Immuno-Oncology Sa Compounds and methods for yap/tead modulation and indications therefor
KR20230050084A (ko) * 2021-10-07 2023-04-14 주식회사 셀진 Plga 및 약물을 함유하는 베타-사이클로덱스트린을 포함하는 약물 전달체
WO2023113479A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
JP2025504908A (ja) 2022-01-28 2025-02-19 アイオバンス バイオセラピューティクス，インコーポレイテッド サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
CN114470237B (zh) * 2022-03-21 2023-12-19 中国科学院长春应用化学研究所 一种类病毒结构基因载体、药物递送系统、其制备方法及其应用
CN115006549B (zh) * 2022-06-16 2024-07-05 湖南科技大学 一种粒径可控及可控降解的酸敏型交联环糊精纳米水凝胶药物递送系统的制备方法
CN115340615B (zh) * 2022-08-12 2023-05-02 同济大学 一种基于环糊精-氨基酸的荧光分子及其合成方法与应用
CA3263309A1 (en) 2022-08-22 2024-02-29 Iambic Therapeutics Inc HER2 COMPOUNDS AND MODULATION METHODS
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
CN119345381B (zh) * 2024-12-23 2025-04-18 上海华之沃生物医药科技有限公司 替曲朵辛偶联物及其制备方法和应用

Family Cites Families (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2131201A (en) 1928-08-04 1938-09-27 Gen Motors Corp Composite clutch
US2129408A (en) 1936-07-02 1938-09-06 Arthur C Davidson Truck stabilizer
US2129401A (en) 1937-09-09 1938-09-06 Botinger Fred Flexible utility ladder
US2131208A (en) 1938-02-26 1938-09-27 Union Switch & Signal Co Remote indication apparatus
US3472835A (en) 1964-02-12 1969-10-14 American Mach & Foundry Schardinger dextrins
US3454530A (en) 1966-03-07 1969-07-08 Leslie C Case Novel polyols which are reaction products of a monoepoxide and a cyclic monoanhydride
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3654261A (en) 1968-06-27 1972-04-04 Cpc International Inc Quaternary ammonium alkoxide alkoxy polyol compounds
USRE32268E (en) 1973-03-01 1986-10-21 Strategic Medical Research Corp. Therapeutic composition and method of therapeutically treating warm blooded animals therewith
GB1390479A (en) 1973-09-05 1975-04-16 I Orch Sinteza Akademii Nauk L Pharmaceutical composition for treatment of parkinsonism
DE2843963A1 (de) 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
DE2842862A1 (de) 1978-10-02 1980-04-10 Boehringer Mannheim Gmbh Verfahren zur bestimmung von ionen, polaren und/oder lipophilen substanzen in fluessigkeiten
CA1190855A (en) 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
JPS58113198A (ja) * 1981-12-26 1983-07-05 Hidetoshi Tsuchida シクロデキストリンが結合したポルフイリン化合物
US4570629A (en) 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
JPS58167613A (ja) 1982-03-26 1983-10-03 Mitsubishi Petrochem Co Ltd 水溶性シクロデキストリン含有重合体の製造法
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0150184A1 (fr) 1983-07-01 1985-08-07 Battelle Memorial Institute Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments
US4525495A (en) 1983-07-22 1985-06-25 The Dow Chemical Company Mineral filled composites
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
CH663951A5 (fr) 1984-10-10 1988-01-29 Nestle Sa Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant.
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
JPH0651725B2 (ja) 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4841081A (en) 1985-10-16 1989-06-20 Osaka Soda Co., Ltd. Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3786309T2 (de) 1986-09-05 1994-02-10 American Cyanamid Co Alkylenoxydblöcke enthaltende Polyester und deren Verwendung als Arzneimittelabgabesysteme.
GB2197720A (en) 1986-11-20 1988-05-25 Nat Res Dev Immobilisation of polynucleotides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0362290A4 (en) 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US4774329A (en) 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US4941996A (en) 1987-10-19 1990-07-17 Minnesota Mining And Manufacturing Company Inclusion complexes providing second harmonic generation
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
US4887778A (en) 1988-06-01 1989-12-19 Universal Instruments Corporation Feeder drive assembly and replaceable section for tape supplying and cover peeling
JPH01319502A (ja) * 1988-06-21 1989-12-25 Showa Denko Kk シクロデキストリン誘導体及びその製造方法
HU200913B (en) 1988-07-28 1990-09-28 Ciklodextrin Kutato Fejlesztoe Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility
MY106598A (en) 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US4902788A (en) 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
US5098793A (en) 1988-09-29 1992-03-24 Uop Cyclodextrin films on solid substrates
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH03221505A (ja) 1990-01-29 1991-09-30 Toppan Printing Co Ltd シクロデキストリンポリマーの合成方法及びシクロデキストリン膜の製造方法
WO1991013100A1 (en) * 1990-03-02 1991-09-05 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
DE4009825A1 (de) 1990-03-27 1991-10-02 Consortium Elektrochem Ind Wasserunloesliche cyclodextrin-polymerisate und verfahren zu deren herstellung
US5139687A (en) 1990-05-09 1992-08-18 The Proctor & Gamble Company Non-destructive carriers for cyclodextrin complexes
JPH0425505A (ja) 1990-05-21 1992-01-29 Toppan Printing Co Ltd シクロデキストリンポリマー及びシクロデキストリン膜の製造方法
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
JPH04106101A (ja) 1990-08-27 1992-04-08 Showa Denko Kk シクロデキストリンポリマーおよびその製造方法
JPH059205A (ja) * 1990-09-28 1993-01-19 Mercian Corp 新規なアドリアマイシン誘導体
DE69103503T2 (de) * 1990-09-28 1995-01-05 Mercian Corp Adriamycinderivate.
KR920702376A (ko) * 1990-10-01 1992-09-03 후지다 히로미찌 시클로덱스트린 폴리머 및 그 폴리머를 이용한 시클로덱스트린막
WO1992009637A1 (en) 1990-11-30 1992-06-11 Toppan Printing Co., Ltd. Process for producing cyclodextrin derivative and polymer containing cyclodextrin immobilized therein
ES2155822T3 (es) 1990-12-06 2001-06-01 Affymetrix Inc Compuestos y su utilizacion en una estrategia de sintesis binaria.
US5148854A (en) 1990-12-11 1992-09-22 Toshiba Kikai Kabushiki Kaisha Counting die cast manufactured goods
NO180605C (no) 1990-12-19 2003-08-28 Geco As Anordning til vektbelastning av streamerkabel
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
EP0602149A1 (en) 1991-09-06 1994-06-22 Commonwealth Scientific And Industrial Research Organisation Composition and method for reducing cholesterol concentration
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
AU3124793A (en) 1991-10-29 1993-06-07 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US6849462B1 (en) 1991-11-22 2005-02-01 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
JP2976154B2 (ja) 1991-11-27 1999-11-10 コニカ株式会社 ハロゲン化銀写真感光材料用固形処理剤
JP3221505B2 (ja) 1992-02-06 2001-10-22 日本信号株式会社 移動体の運行管理装置
US5219980A (en) 1992-04-16 1993-06-15 Sri International Polymers biodegradable or bioerodiable into amino acids
JPH05331074A (ja) 1992-05-27 1993-12-14 Nippon Oil & Fats Co Ltd 薬物運搬体
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
IT1256134B (it) 1992-09-09 1995-11-29 Luigi Boltri Sali lipofili contenenti isotopi neutron attivabili e composizioni che li contengono
US5482719A (en) 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
ATE151778T1 (de) 1992-11-30 1997-05-15 Ciba Geigy Ag Polymerisierbare kohlenhydratester, polymere daraus und deren verwendung
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
US5840485A (en) 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
TW328535B (en) 1993-07-02 1998-03-21 Novartis Ag Functional photoinitiators and their manufacture
JP3288149B2 (ja) 1993-08-05 2002-06-04 日本食品化工株式会社 シクロデキストリンポリマー及びその製造方法
RU2094059C1 (ru) 1993-08-30 1997-10-27 Московский государственный университет, химический факультет Способ транспорта нейротропных препаратов в мозг
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
TW307775B (en) 1994-02-15 1997-06-11 Novartis Erfind Verwalt Gmbh Unsaturated carbohydrate derivatives, polymers thereof and their use
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
JPH07316205A (ja) 1994-03-30 1995-12-05 D D S Kenkyusho:Kk シクロデキストリン誘導体
HU218280B (en) 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
US6589736B1 (en) 1994-11-22 2003-07-08 The Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5716594A (en) 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5776842A (en) 1994-06-23 1998-07-07 Cellresin Technologies, Llc Cellulosic web with a contaminant barrier or trap
AU689924B2 (en) 1994-06-23 1998-04-09 Affymax Technologies N.V. Photolabile compounds and methods for their use
US5679773A (en) 1995-01-17 1997-10-21 Affymax Technologies N.V Reagants and methods for immobilized polymer synthesis and display
US5494854A (en) 1994-08-17 1996-02-27 Texas Instruments Incorporated Enhancement in throughput and planarity during CMP using a dielectric stack containing HDP-SiO2 films
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5548932A (en) * 1994-11-08 1996-08-27 Maxcess Technologies, Inc. Adjustable cable tray support system
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US5728804A (en) 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
US6667293B1 (en) 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ES2448467T3 (es) 1996-03-12 2014-03-14 Pg-Txl Company, L.P. Profármacos solubles en agua
DE19612768A1 (de) 1996-03-29 1997-10-02 Basf Ag Cyclodextringruppen enthaltende Polymere, Verfahren zu ihrer Herstellung und ihre Verwendung
JP3830198B2 (ja) 1996-03-29 2006-10-04 東光薬品工業株式会社 超分子構造高分子集合体を用いた皮膚透過性インドメタシン外用剤
JPH11514388A (ja) * 1996-04-03 1999-12-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア シクロデキストリン化合物ならびにその製造法および使用
DE19629494A1 (de) 1996-07-09 1998-01-15 Schering Ag Pseudopolyrotaxane
US5844030A (en) 1996-07-09 1998-12-01 Andros; Nicholas Charged ion cleaning devices and cleaning system
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
WO1998020967A1 (en) 1996-11-14 1998-05-22 Affymetrix, Inc. Chemical amplification for the synthesis of patterned arrays
JPH10158195A (ja) 1996-11-28 1998-06-16 Res Inst For Prod Dev 配位結合を利用した薬物−高分子複合体製剤の調製方法
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
HUP9700632A3 (en) 1997-03-24 1999-10-28 Cyclolab Ciklodextrin Kutato F Pharmaceutical compositions containing propylamine derivative and cyclodextrine and process for producing the same
AU7124598A (en) 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
AU743204B2 (en) 1997-04-23 2002-01-24 University Of Otago Controlled release of ophthalmic compositions
WO1998049350A1 (en) 1997-04-30 1998-11-05 Regents Of The University Of Minnesota In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO1998056370A2 (en) 1997-06-13 1998-12-17 Johns Hopkins University School Of Medicine Therapeutic nanospheres
DE19726186A1 (de) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
JPH11100401A (ja) 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
US6410342B1 (en) 1997-08-19 2002-06-25 Pharmacopeia, Inc. Method and apparatus for controlled photoelution
IL134842A0 (en) 1997-09-15 2001-05-20 Genetic Immunity Llc Method of delivering genes to antigen presenting cells of the skin
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
GB9801109D0 (en) 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
US6426184B1 (en) 1998-02-11 2002-07-30 The Regents Of The University Of Michigan Method and apparatus for chemical and biochemical reactions using photo-generated reagents
IT1298732B1 (it) 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
WO1999061062A1 (en) 1998-05-29 1999-12-02 Massachusetts Institute Of Technology Cyclodextrin complexes
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
AU2162700A (en) 1998-12-04 2000-06-26 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
EA006294B1 (ru) 1998-12-23 2005-10-27 Дж.Д.Сирл Энд Ко. Применение комбинации целекоксиба и гемцитабина в комбинированном способе лечебного воздействия при лечении рака поджелудочной железы
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
FR2789685B1 (fr) * 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
FR2792942B1 (fr) * 1999-04-29 2001-06-08 Commissariat Energie Atomique Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
JP2003501440A (ja) 1999-06-07 2003-01-14 マイラス コーポレーション 反応活性なジスルフィド結合を含む化合物
DK1102785T3 (da) 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6420378B1 (en) 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
WO2001037665A1 (en) 1999-11-29 2001-05-31 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
US20010041706A1 (en) 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
WO2001074401A2 (en) * 2000-03-31 2001-10-11 Supergen, Inc. Camptothecin complexes
JP2001288097A (ja) 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US6664228B1 (en) 2000-08-10 2003-12-16 Ceramoptec Industries, Inc. Photoselective marking of biological targets
US6602707B2 (en) 2000-08-01 2003-08-05 Oregon Health & Science University Mammalian cell surface DNA receptor-encoding nucleic acid
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1352072A4 (en) 2001-01-17 2004-09-01 Zycos Inc NUCLEIC ACID RELEASE PREPARATIONS
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6828392B2 (en) 2001-08-28 2004-12-07 Carlsberg A/S Hydroxy and amine functionalized resins
WO2003020305A1 (en) 2001-08-30 2003-03-13 Baylor College Of Medecine Methionine restriction for cancer therapy
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
CA2465860A1 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20030134824A1 (en) 2001-11-12 2003-07-17 Ronald Breslow Beta-cyclodextrin dimers and phthalocyanines and uses thereof
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US6527887B1 (en) 2002-01-18 2003-03-04 Mach I, Inc. Polymeric cyclodextrin nitrate esters
JP4625637B2 (ja) * 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
JP2005518470A (ja) 2002-02-22 2005-06-23 インサート セラピューティクス インコーポレイテッド 炭水化物−修飾ポリマー組成物及びその使用法
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
EP1562627A4 (en) 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US20040047835A1 (en) 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
CN1694728B (zh) 2002-09-06 2011-12-28 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
AU2003278764C1 (en) 2002-09-06 2010-09-16 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2004032862A2 (en) * 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
JP2006504743A (ja) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
US7495099B2 (en) 2002-10-31 2009-02-24 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
ATE517992T1 (de) 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
CN1216057C (zh) 2003-03-28 2005-08-24 贵州省生物研究所 喜树碱类似物的衍生物及其制备方法
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2006004574A2 (en) 2004-02-19 2006-01-12 Abbott Laboratories Method for using gamma cyclodextrin to control blood glucose and insulin secretion
JP2008504809A (ja) 2004-06-04 2008-02-21 ジェネンテック・インコーポレーテッド Ｅｇｆｒ突然変異
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
RU2400232C2 (ru) 2004-12-15 2010-09-27 Новартис Аг Комбинации терапевтических агентов для лечения рака
TW200640493A (en) 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
KR20190062506A (ko) 2005-02-18 2019-06-05 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
BRPI0608173A2 (pt) 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
WO2007001868A1 (en) 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations
JP4994618B2 (ja) 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US8143236B2 (en) 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
US7897568B2 (en) 2006-03-03 2011-03-01 Vinay K. Singh Compositions for treatment of cancer
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
TWI528976B (zh) 2006-12-13 2016-04-11 斯茹林製藥公司 用於醫物傳遞之以環糊精為基之聚合物
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20110177161A1 (en) 2007-05-24 2011-07-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
US20100273859A1 (en) 2007-12-14 2010-10-28 The Brigham And Women's Hospital, Inc. Treatment and prevention of hiv infection
EP2283133A2 (en) 2008-04-04 2011-02-16 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
TW201010732A (en) 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
ES2704986T3 (es) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
EA201171195A8 (ru) 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
AU2010295646B2 (en) 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
US20130029909A1 (en) 2009-09-15 2013-01-31 John Ryan Treatment of cancer
US20110245201A1 (en) 2009-09-15 2011-10-06 John Ryan Treatment of cancer
US20110237540A1 (en) 2009-11-23 2011-09-29 Crawford Thomas C Cyclodextrin-based polymers for therapeutic delivery
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2012044832A1 (en) 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
JP6208131B2 (ja) 2011-09-12 2017-10-04 ユニヴェルシテイト ヘントＵｎｉｖｅｒｓｉｔｅｉｔ Ｇｅｎｔ 結腸直腸ガンのニューレグリン−１に基づく予後予測及び治療層別化
US9200035B2 (en) 2011-10-21 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bifunctional compounds
EP2903644A4 (en) 2012-10-05 2016-03-09 Cerulean Pharma Inc TREATMENT OF CANCER

Also Published As

Publication number Publication date
US20130165405A1 (en) 2013-06-27
US20150165055A1 (en) 2015-06-18
US20130039880A1 (en) 2013-02-14
MX367615B (es) 2019-08-28
US20140288023A1 (en) 2014-09-25
KR101857900B1 (ko) 2018-05-14
JP2011080089A (ja) 2011-04-21
US20040077595A1 (en) 2004-04-22
US20120289480A1 (en) 2012-11-15
US8609081B2 (en) 2013-12-17
CN102516417B (zh) 2014-12-10
AU2003278764B2 (en) 2010-02-04
JP2006502301A (ja) 2006-01-19
KR101476067B1 (ko) 2014-12-23
US8110179B2 (en) 2012-02-07
KR20050038039A (ko) 2005-04-25
JP2012082220A (ja) 2012-04-26
US20170369651A1 (en) 2017-12-28
HK1072202A1 (en) 2005-08-19
US20140044669A1 (en) 2014-02-13
EP1534340A2 (en) 2005-06-01
US8580243B2 (en) 2013-11-12
AU2003278764C1 (en) 2010-09-16
KR20180004322A (ko) 2018-01-10
BRPI0314042B8 (pt) 2021-05-25
TWI366464B (en) 2012-06-21
EP1534340B1 (en) 2011-11-16
ATE533513T1 (de) 2011-12-15
US8518388B2 (en) 2013-08-27
ES2377318T3 (es) 2012-03-26
WO2004022099A2 (en) 2004-03-18
CA2497792A1 (en) 2004-03-18
EP2277551B1 (en) 2013-05-08
PT1534340E (pt) 2012-03-13
BR0314042A (pt) 2005-07-05
BR122012021252B8 (pt) 2021-05-25
AU2009251190C1 (en) 2013-03-14
US20210128516A1 (en) 2021-05-06
EP2402036B1 (en) 2018-02-14
EP3332811A1 (en) 2018-06-13
US20080058427A1 (en) 2008-03-06
TW201221132A (en) 2012-06-01
WO2004022099A3 (en) 2004-10-28
TW200423947A (en) 2004-11-16
KR101268258B1 (ko) 2013-05-31
KR102008768B1 (ko) 2019-08-08
US7270808B2 (en) 2007-09-18
EP2277551A2 (en) 2011-01-26
BR122012021252B1 (pt) 2018-07-10
JP5681646B2 (ja) 2015-03-11
US20120301424A1 (en) 2012-11-29
IL234715A0 (en) 2014-11-30
EP2402036A1 (en) 2012-01-04
US8399431B2 (en) 2013-03-19
KR20130033467A (ko) 2013-04-03
CN104383554B (zh) 2018-06-08
CY1112362T1 (el) 2015-12-09
US20130129665A1 (en) 2013-05-23
US20130196945A1 (en) 2013-08-01
US8603454B2 (en) 2013-12-10
US20130190450A1 (en) 2013-07-25
IL234716A0 (en) 2014-11-30
US20130156721A1 (en) 2013-06-20
US8404662B2 (en) 2013-03-26
ES2417324T3 (es) 2013-08-07
HK1151467A1 (en) 2012-02-03
CA2497792C (en) 2014-08-05
AU2009251190B2 (en) 2012-08-09
ES2666694T3 (es) 2018-05-07
HK1254600A1 (en) 2019-07-26
CY1114941T1 (el) 2016-12-14
PT2277551E (pt) 2013-08-22
JP5586487B2 (ja) 2014-09-10
JP5934743B2 (ja) 2016-06-15
US8475781B2 (en) 2013-07-02
US8580242B2 (en) 2013-11-12
KR20160106223A (ko) 2016-09-09
CN102516417A (zh) 2012-06-27
US9550860B2 (en) 2017-01-24
JP2014167022A (ja) 2014-09-11
TWI422379B (zh) 2014-01-11
US8580244B2 (en) 2013-11-12
AU2009251190A1 (en) 2010-01-21
KR20120104412A (ko) 2012-09-20
US20120178711A1 (en) 2012-07-12
US8314230B2 (en) 2012-11-20
US20130131013A1 (en) 2013-05-23
US20120065368A1 (en) 2012-03-15
US20120283214A1 (en) 2012-11-08
EP2277551A3 (en) 2011-11-23
AU2003278764A1 (en) 2004-03-29
CN104383554A (zh) 2015-03-04
US8389499B2 (en) 2013-03-05
US8680202B2 (en) 2014-03-25
US20130203700A1 (en) 2013-08-08
BRPI0314042B1 (pt) 2020-02-11
US8252276B2 (en) 2012-08-28
KR20140070676A (ko) 2014-06-10

Similar Documents

Publication Publication Date Title
MX367615B (es) Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
TW200640493A (en) Cyclodextrin-based polymers for therapeutics delivery
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
Ossipov Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering
Venditto et al. Cancer therapies utilizing the camptothecins: a review of the in vivo literature
ATE342054T1 (de) Verfahren und zusammansetzung zur behandlung von krebs
Baraldi et al. Hybrid molecules between distamycin A and active moieties of antitumor agents
EP2548582B1 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
CA2387058A1 (en) Injection vehicle for polymer-based formulations
WO2007004067A3 (en) Methods and compositions for the delivery of biologically active agents
WO2006060533A3 (en) Conjugates of 1, 8-bis-naphthalimides with an antibody
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
PT1560854E (pt) Taxanos ligados covalentemente ao ácido hialurónico ou a derivados do ácido hialurónico
WO2004105782A3 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
WO2007064345A3 (en) Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
TN2010000002A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MXPA06011965A (es) Conjugados biologicamente activos mejorados.
EP1430061A4 (en) INCLUSION COMPOUND CONTAINING CUCURBITURIL DERIVATIVES AS RECEPTOR MOLECULE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
IL154993A0 (en) High affinity small molecule c5a receptor modulators
Brulikova et al. DNA interstrand cross-linking agents and their chemotherapeutic potential
Henke et al. Macromolecular Pt (IV) prodrugs from poly (organo) phosphazenes
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
WO2002087497A3 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
Park et al. Water-soluble heparin–PTX conjugates for cancer targeting
WO2006073430A3 (en) Therapeutic delivery system comprising a high molecular weight peg-like compound

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration